Tempest enters China partnership for IIT trials
Tempest signed an agreement with Hebei Senlang to conduct investigator-initiated trials in China, generating twenty evaluable patient datasets to facilitate potential business development transactions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day